## KINETICS AND MEMBRANE INCORPORATION OF INTRAVENOUS N-3 POLYUNSATURATED FATTY ACIDS ADMINISTRATED AS A 1 HOUR FAST INFUSION.

M. Rohrer<sup>\*1</sup>, R. L. Chioléro<sup>1</sup>, L. Soguel Alexander<sup>1</sup>, P. Voirol<sup>1</sup>, H. Henry<sup>2</sup>, L. Tappy<sup>3</sup>, Y. A. Carpentier<sup>4</sup>, M. M. Berger<sup>1</sup> <sup>1</sup>Department of Adult Intensive Care Medicine, <sup>2</sup>Clinical Chemistry Laboratory, Centre Hospitalier Universitaire Vaudois, <sup>3</sup>Department of Physiology, University of Lausanne, Lausanne, Switzerland, <sup>4</sup>Laboratories of Experimental Surgery, Brussels Free University, Brussels, Belgium

**Disclosure of Interest**I declare that I do not have any affiliation with or financial interest in a commercial organisation that poses a conflict of interest.

**Rationale:** A 3 hr 0.2 g/kg intravenous fish oil (FO) infusion is associated with a significant incorporation of EPA and DHA into platelet membranes and blunts the physiological responses to endotoxin (Pluess et al, ICM 2007). Aiming at facilitating clinical use, we hypothesized that a shorter infusion time (1 hr) might be associated with similar EPA/DHA membrane incorporation. The present study aims at defining the timing of incorporation after a 1 hour infusion and clinical tolerance.

**Methods:** FO lipid emulsion (Omegaven®, Fresenius Kabi) was infused in 1 hr (0.2 g FO/kg) to 8 healthy volunteers (age 42.1±8.5 years; BMI 23.2±1.6). Blood samples: at baseline (t0), 15, 30, 60, 120, 240 and 360 minutes. Analysis: platelets' membrane phospholipids fatty acid composition, triglycerides (TG) and free fatty acids (FFA) plasma concentrations. Statistics: mean±SD, ANOVA, Wilcoxon signed-rank.

**Results:** Plasma TG peaked at t60 ( $5.2\pm1.1 \text{ mmol/L}$ , 5-fold baseline value), with a return to pre-infusion values by t360 (t1/2: 100±35 min). Membrane EPA and DHA enrichments were significant already at t60 at the end of the perfusion and continued to increase until t360. Peak FFA concentrations : 0.6 mmol/L at t60. Clinical tolerance: no adverse side effect was observed.

## Table:

	<b>T000</b>	<b>T060</b>	<b>T360</b>
TG (mmol/L)	1.2±0.5	5.2±1.1*	1.2±0.6
EPA (% of total FA)	$0.48 \pm 0.17$	0.66±0.2*	0.86±0.19*
DHA (% of total FA)	$2.58 \pm 0.74$	2.78±0.77*	2.95±0.71*
n6/n3	7.36±1.42	6.81±1.31*	6.2±0.9*

\*: *p* < .005 vs baseline (t0)

**Conclusions:** These data on n-3 PUFA lipid emulsion infusion are new. The 1 hr rate of infusion, which corresponds to 4 times the recommended rate is safe, based on peak TG and FFA levels below toxic thresholds. A significant incorporation of EPA and DHA into the platelets' membrane is observable already after 1 hr, opening new therapeutic perspectives.